Kerry Culm

Company: ModeX Therapeutics

Job title: Head of Translational Medicine & Early Development

Seminars:

Moving Beyond Bispecifics with Multivalent T cell Engagers in Solid Tumors 1:30 pm

ModeX’s multispecific antibody platform technology designed for syngergistic targeting and streamlined manufacturing in a single product The pathway from design, creation, and characterization to the clinic Utilizing information about validated targets and known immune mechanisms to characterize clinical safety and efficacy in patients with advanced solid tumorsRead more

day: Day Two